Supriya Lifescience

Supriya Lifescience Net Debt / EBITDA

The Net Debt to EBITDA of Supriya Lifescience (SUPRIYA.NS) as of Oct 24, 2026 is -0.27. In the previous year, Net Debt to EBITDA was -0.27 — a change of -2.64% (higher).

Net Debt / EBITDA

-0.27

YoY

-2.64%

Last updated:

Net Debt to EBITDA of Supriya Lifescience is 2026 -0.27 . Net Debt to EBITDA of Supriya Lifescience was 2025 -0.27 . It decreases by -2.64% higher compared to the previous year.

The Supriya Lifescience Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2019
1.20 INR
Jan 1, 2020
0.09 INR
Jan 1, 2021
-0.08 INR
Jan 1, 2022
-0.89 INR
Jan 1, 2023
-0.99 INR
Jan 1, 2024
-0.38 INR
Jan 1, 2025
-0.27 INR
Jan 1, 2026
-0.27 INR
The Supriya Lifescience Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
-0.27-2.64%
-0.27-27.95%
-0.38-61.64%
-0.99+10.64%
-0.89+972.31%
-0.08-194.75%
0.09-92.70%
1.20-78.26%
5.53—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Supriya Lifescience Stock analysis

What does Supriya Lifescience do? Supriya Lifescience Ltd. generates revenue through the manufacturing and export of active pharmaceutical ingredients (APIs) focused on niche therapeutic segments. The company produces approximately 38 API products, including Chlorphenamine Maleate, Pheniramine Maleate, and Cetirizine DiHCL, which address antihistamine, analgesic, vitamin, anesthetics, and anti-asthma therapies. These products are exported to around 86 countries, targeting pharmaceutical manufacturers and healthcare providers seeking specialized chemical compounds for drug formulations. The firm's manufacturing facilities in Maharashtra support the production of bulk drugs and pharmaceutical chemicals, with a strong emphasis on research and development to maintain its niche market position. The company's product portfolio includes specialized compounds such as Bisoprolol Fumarate, Nicorandil, and Mecobalamin, which cater to specific medical needs in cardiovascular and neurological treatments. By concentrating on high-demand therapeutic areas like antihistamines and anti-asthma solutions, Supriya Lifescience Ltd. serves pharmaceutical companies globally that require reliable sources of API raw materials. Its export-driven model ensures steady demand from international clients across diverse healthcare markets. Supriya Lifescience Ltd. leverages its research and development capabilities to develop and refine its API offerings, ensuring compliance with global pharmaceutical standards. The firm's focus on niche products allows it to differentiate itself in a competitive market, attracting buyers who prioritize specialized chemical solutions over generic alternatives. With a manufacturing base in Maharashtra, the company efficiently scales production to meet the growing global demand for its targeted therapeutic APIs. Supriya Lifescience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Supriya Lifescience stock

Net Debt to EBITDA of Supriya Lifescience is -0.27 in 2026.

Net Debt to EBITDA of Supriya Lifescience changed from -0.27 to -0.27, representing a -2.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Supriya Lifescience since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Supriya Lifescience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Supriya Lifescience

All Key Metrics — Supriya Lifescience